This article discusses the potential of MIS416 adjuvant, a vaccine adjuvant and immunogen co-delivery system, to provide adequate immunostimulation to overcome host factors that may limit the success of therapeutic vaccines.
Gill A. Webster, PhD
Advertisement
Gill A. Webster, PhD, is chief scientific officer at Virionyx Corporation Ltd.
Articles by Gill A. Webster, PhD
Advertisement
Latest Updated Articles
The Therapeutic Vaccine Potential of MIS416 AdjuvantJanuary 2nd 2009
Advertisement
Advertisement